Victor R. Vaz

1.4k total citations
12 papers, 111 citations indexed

About

Victor R. Vaz is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Victor R. Vaz has authored 12 papers receiving a total of 111 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 3 papers in Surgery. Recurrent topics in Victor R. Vaz's work include Lung Cancer Treatments and Mutations (6 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Pancreatic and Hepatic Oncology Research (2 papers). Victor R. Vaz is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Pancreatic and Hepatic Oncology Research (2 papers). Victor R. Vaz collaborates with scholars based in United States, Taiwan and Brazil. Victor R. Vaz's co-authors include Mark M. Awad, Biagio Ricciuti, Mizuki Nishino, Joao V. Alessi, Stephanie Alden, Kathleen L. Pfaff, Scott J. Rodig, James Lindsay, Bijaya Sharma and Kristen D. Felt and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and CHEST Journal.

In The Last Decade

Victor R. Vaz

8 papers receiving 110 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Victor R. Vaz United States 3 78 36 27 23 10 12 111
Yuanyuan Bao China 5 83 1.1× 32 0.9× 18 0.7× 55 2.4× 18 1.8× 14 125
J. Remon Masip France 5 108 1.4× 95 2.6× 15 0.6× 12 0.5× 8 0.8× 23 135
Tomoyuki Ishiguro Japan 6 102 1.3× 40 1.1× 48 1.8× 10 0.4× 4 0.4× 10 129
Almut Mecke Switzerland 6 105 1.3× 40 1.1× 35 1.3× 62 2.7× 18 1.8× 10 150
N. Zanaletti Italy 8 133 1.7× 35 1.0× 26 1.0× 45 2.0× 14 1.4× 20 156
Keisuke Onoi Japan 3 114 1.5× 72 2.0× 42 1.6× 11 0.5× 16 1.6× 5 157
Jennifer Friedmann Canada 6 108 1.4× 58 1.6× 40 1.5× 21 0.9× 9 0.9× 16 157
David García-Illescas Spain 6 71 0.9× 53 1.5× 27 1.0× 31 1.3× 7 0.7× 15 156
Hanmei Lou China 6 96 1.2× 28 0.8× 42 1.6× 32 1.4× 17 1.7× 14 154
Ria Uhlig Germany 3 44 0.6× 21 0.6× 23 0.9× 8 0.3× 6 0.6× 6 79

Countries citing papers authored by Victor R. Vaz

Since Specialization
Citations

This map shows the geographic impact of Victor R. Vaz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Victor R. Vaz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Victor R. Vaz more than expected).

Fields of papers citing papers by Victor R. Vaz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Victor R. Vaz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Victor R. Vaz. The network helps show where Victor R. Vaz may publish in the future.

Co-authorship network of co-authors of Victor R. Vaz

This figure shows the co-authorship network connecting the top 25 collaborators of Victor R. Vaz. A scholar is included among the top collaborators of Victor R. Vaz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Victor R. Vaz. Victor R. Vaz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Mohan, Dipika R., David M. Meredith, Beatriz Santana Soares, et al.. (2025). Non-recurrent mutations and copy number changes predominate pituitary adenoma genomes. European Journal of Endocrinology. 192(5). 590–602.
2.
Vaz, Victor R., Biagio Ricciuti, Joao V. Alessi, et al.. (2024). Response to Crizotinib After Entrectinib Resistance in ROS1 -Rearranged, MET -Amplified Lung Adenocarcinoma. JCO Precision Oncology. 8(8). e2400394–e2400394.
3.
4.
Federico, Alessandro Di, Stephanie Alden, James W. Smithy, et al.. (2024). Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer. Annals of Oncology. 35(10). 902–913. 24 indexed citations
5.
Nishino, Mizuki, Xinan Wang, Biagio Ricciuti, et al.. (2023). Advanced non-small-cell lung cancer treated with first-line pembrolizumab plus chemotherapy: tumor response dynamics as a marker for survival. European Radiology. 33(10). 7284–7293. 1 indexed citations
6.
Lamberti, Giuseppe, Biagio Ricciuti, Victor R. Vaz, et al.. (2022). 451 Serum albumin predicts outcome in patients with extensive stage small-cell lung cancer (ES-SCLC) receiving first-line combination of PD-(L)1 inhibitors and platinum-etoposide chemotherapy. Regular and Young Investigator Award Abstracts. A471–A471. 1 indexed citations
7.
Alessi, Joao V., Zihan Wei, Biagio Ricciuti, et al.. (2022). Distinct genomic and immunophenotypic features of solid-predominant versus nonsolid-predominant stage I lung adenocarcinomas and association with disease recurrence after surgical resection.. Journal of Clinical Oncology. 40(16_suppl). 8514–8514. 1 indexed citations
8.
Alessi, Joao V., Biagio Ricciuti, Federica Pecci, et al.. (2022). Immunophenotypic correlates and response to first-line pembrolizumab among elderly patients with PD-L1-high (≥ 50%) non–small cell lung cancer.. Journal of Clinical Oncology. 40(16_suppl). 9054–9054.
9.
Pecci, Federica, Biagio Ricciuti, Joao V. Alessi, et al.. (2022). Activating MET kinase domain mutations define a novel molecular subtype of non–small cell lung cancer that is clinically targetable with the MET inhibitor elzovantinib (TPX-0022).. Journal of Clinical Oncology. 40(16_suppl). 9124–9124. 1 indexed citations
10.
11.
Alessi, Joao V., Biagio Ricciuti, Stephanie Alden, et al.. (2021). Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer. Journal for ImmunoTherapy of Cancer. 9(11). e003536–e003536. 63 indexed citations
12.
Ricciuti, Biagio, Joao V. Alessi, Stephanie Alden, et al.. (2021). 312 Three-year outcomes with first-line pembrolizumab for metastatic non–small-cell lung cancer (NSCLC) with a very high PD-L1 tumor proportion score (TPS) ≥ 90%. SHILAP Revista de lepidopterología. A336–A336. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yuanyuan Bao Breakdown of academic impact, for papers by J. Remon Masip Breakdown of academic impact, for papers by Tomoyuki Ishiguro Breakdown of academic impact, for papers by Almut Mecke Breakdown of academic impact, for papers by N. Zanaletti Breakdown of academic impact, for papers by Keisuke Onoi Breakdown of academic impact, for papers by Jennifer Friedmann Breakdown of academic impact, for papers by David García-Illescas Breakdown of academic impact, for papers by Hanmei Lou Breakdown of academic impact, for papers by Ria Uhlig
Rankless by CCL
2026